Rubio-Guerra Alberto F, Vargas-Robles Hilda, Vargas-Ayala German, Rodríguez-Lopez Leticia, Castro-Serna David, Escalante-Acosta Bruno A
Mexican Group for Basic and Clinical Research in Internal Medicine, A.C., Clinic Research Unit, Hospital General de Ticomán SS DF, Plan de San Luis S/N esq Bandera, C.P. 07330, México DF.
Ther Adv Cardiovasc Dis. 2011 Aug;5(4):193-7. doi: 10.1177/1753944711415307. Epub 2011 Jul 7.
Adiponectin is secreted from adipose tissue and exhibits a protective effect against cardiovascular disease; plasma adiponectin concentrations are decreased in type 2 diabetic and in hypertensive patients.
The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on adiponectin levels in hypertensive type 2 diabetic patients.
A total of 40 type 2 diabetic patients with never-treated hypertension were randomly assigned to two groups. One group received FDTV 180 mg + T 2 mg, once a day; the other group received T 2 mg once a day, administered for 3 months in both groups. Adiponectin was measured by enzyme-linked immunosorbent assay (ELISA) at the beginning and end of the study. Patients were evaluated monthly for blood pressure, fasting serum glucose and adverse events. Statistical analysis was performed with analysis of variance (ANOVA).
All patients experienced a significant reduction of blood pressure. Both therapeutics regimens increased the levels of adiponectin, However, FDTV produces a higher increase in the levels of the hormone (8.15 ± 4.6 to 10.96 ± 5.6 µg/ml) when compared with the T treatment (7.64 ± 3.8 to 8.92 ± 4.4 µg/ml), p < 0.05. None of the patients suffered adverse events.
Our results show that the addition of FDTV to T produced a greater increase on adiponectin levels than trandolapril alone.
脂联素由脂肪组织分泌，对心血管疾病具有保护作用；2型糖尿病患者和高血压患者的血浆脂联素浓度降低。
本研究旨在比较群多普利（T）及其与维拉帕米的固定剂量复方制剂（FDTV）对2型糖尿病高血压患者脂联素水平的影响。
总共40例未经治疗的2型糖尿病高血压患者被随机分为两组。一组接受FDTV 180毫克+T 2毫克，每日一次；另一组接受T 2毫克，每日一次，两组均给药3个月。在研究开始和结束时通过酶联免疫吸附测定（ELISA）测量脂联素。每月对患者进行血压、空腹血清葡萄糖和不良事件评估。采用方差分析（ANOVA）进行统计分析。
所有患者血压均显著降低。两种治疗方案均提高了脂联素水平，然而，与T治疗（7.64±3.8至8.92±4.4微克/毫升）相比，FDTV使该激素水平升高幅度更大（8.15±4.6至10.96±5.6微克/毫升），p<0.05。所有患者均未出现不良事件。
我们的结果表明，T联合FDTV比单独使用群多普利能使脂联素水平升高幅度更大。
